Gilead Sciences Inks $247M Deal For HIV Antitrust Claims - Law360 UK

Gilead Sciences Inks $247M Deal For HIV Antitrust Claims – Law360 UK

Source Node: 2205422
By Matthew Perlman (August 10, 2023, 5:32 PM EDT) — Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial settlement on the eve of a trial earlier this year….

Time Stamp:

More from Law 360